Page 15 - Clinical Program News Today

Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress Significantly advanced varoglutamstat EU and U.S. clinical studies, VIVIAD and VIVA-MIND

– First preclinical data presented for the next generation of the UltraCAR-T platform utilizing a mesothelin (MSLN) chimeric antigen receptor (CAR) – – MSLN is...

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RGX-202,...

L.A. city and county leaders celebrated the grand opening of Silva Crossing, a supportive housing project in Sylmar that features 56 studio-bedrooms.

- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023 – - Completed...

30.03.2023 - - Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023 – - Completed majority of non-clinical and clinical prelaunch measures for brilaroxazine New Drug ...

Debt investment, FVOCI - equity investment or FVTPL. Financial assets are not reclassified subsequent to their initial recognition unless the Company changes its business model for... | March 29, 2023

BDC-1001 elicited objective clinical responses, including multiple PRs and long-term stable disease, across a diverse set of solid tumor types in monotherapy and in combination with... | March 29, 2023

BDC-1001 elicited objective clinical responses, including multiple PRs and long-term stable disease, across a diverse set of solid tumor types in monotherapy and in combination with nivolumabData support selection of a recommended Phase 2 dose and advance...

Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2 2023 Strong balance sheet with sufficient cash expected to fund operations into mid-2024 ... | March 23, 2023